R DLBCL): A Systematic Literature Review (SLR) (original) (raw)

Clinical Lymphoma, Myeloma & Leukemia, 2021

Abstract

Context Limited published SLRs exist on third-line and greater (3L+) treatment of R/R DLBCL, despite recent approvals of newer therapies. Objective To conduct an SLR evaluating the efficacy, safety, and PROs of therapies for 3L+ R/R DLBCL. Design SLR in accordance with the Cochrane Handbook for Systematic Reviews of Interventions and European Union Health Technology Assessment requirements; publications prior to November 2020 in MEDLINE, MEDLINE In-Process, Embase, and Cochrane Library databases; supplemented by a gray literature search. Main Outcome Measures Efficacy, safety, and PROs. Results Post-screening of 9,901 records, 143 publications covering 40 studies were identified. Seven studies were reported as interventions of interest: chimeric antigen receptor T-cell therapy (CAR-T: 3), antibody–drug conjugates (ADC: 2), nuclear export inhibitor (S: 1), aza-anthracenedione analogue (P: 1), and chemo/chemoimmunotherapy (Ch: 2). Wide ranges of efficacy outcomes were reported. CAR-T ...

Srikanth Ambati hasn't uploaded this paper.

Let Srikanth know you want this paper to be uploaded.

Ask for this paper to be uploaded.